KINIKSA PHARMACEUTICALS-A (KNSA)
BMG5269C1010 - Common Stock
We assign a fundamental rating of 4 out of 10 to KNSA. KNSA was compared to 588 industry peers in the Biotechnology industry. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability. KNSA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
KNSA had positive earnings in the past year.
KNSA had a positive operating cash flow in the past year.
In multiple years KNSA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
1.2 Ratios
KNSA has a Return On Assets of 1.66%. This is amongst the best in the industry. KNSA outperforms 94.88% of its industry peers.
Looking at the Return On Equity, with a value of 2.00%, KNSA belongs to the top of the industry, outperforming 94.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.66% | ||
| ROE | 2% | ||
| ROIC | N/A |
ROA(3y)-8.42%
ROA(5y)-27.01%
ROE(3y)-11.95%
ROE(5y)-31.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 2.86%, KNSA belongs to the best of the industry, outperforming 95.05% of the companies in the same industry.
KNSA has a better Gross Margin (87.75%) than 91.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.86% | ||
| GM | 87.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KNSA does not have a ROIC to compare to the WACC, probably because it is not profitable.
KNSA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KNSA has more shares outstanding
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.56 indicates that KNSA is not in any danger for bankruptcy at the moment.
KNSA's Altman-Z score of 8.56 is amongst the best of the industry. KNSA outperforms 85.32% of its industry peers.
There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.56 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 4.21 indicates that KNSA has no problem at all paying its short term obligations.
KNSA has a Current ratio of 4.21. This is comparable to the rest of the industry: KNSA outperforms 47.78% of its industry peers.
A Quick Ratio of 3.79 indicates that KNSA has no problem at all paying its short term obligations.
With a Quick ratio value of 3.79, KNSA perfoms like the industry average, outperforming 44.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.21 | ||
| Quick Ratio | 3.79 |
3. Growth
3.1 Past
KNSA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -96.03%.
KNSA shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.69%.
EPS 1Y (TTM)-96.03%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-38.89%
Revenue 1Y (TTM)27.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q65.17%
3.2 Future
Based on estimates for the next years, KNSA will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.57% on average per year.
KNSA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.74% yearly.
EPS Next Y-193.5%
EPS Next 2Y-48.57%
EPS Next 3Y-21.61%
EPS Next 5Y-26.57%
Revenue Next Year49.15%
Revenue Next 2Y41.27%
Revenue Next 3Y33.9%
Revenue Next 5Y15.74%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 176.36 indicates a quite expensive valuation of KNSA.
Based on the Price/Earnings ratio, KNSA is valued cheaper than 94.20% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.55, KNSA is valued quite expensively.
Based on the Price/Forward Earnings ratio of 407.53, the valuation of KNSA can be described as expensive.
Based on the Price/Forward Earnings ratio, KNSA is valued cheaper than 93.86% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.92, KNSA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 176.36 | ||
| Fwd PE | 407.53 |
4.2 Price Multiples
94.71% of the companies in the same industry are more expensive than KNSA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.13 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as KNSA's earnings are expected to decrease with -21.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.57%
EPS Next 3Y-21.61%
5. Dividend
5.1 Amount
KNSA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KINIKSA PHARMACEUTICALS-A
NASDAQ:KNSA (5/1/2024, 3:15:00 PM)
After market: 19.4 0 (0%)19.4
+0.68 (+3.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.37B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 176.36 | ||
| Fwd PE | 407.53 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.66% | ||
| ROE | 2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 2.86% | ||
| GM | 87.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.21 | ||
| Quick Ratio | 3.79 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-96.03%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-193.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.69%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y